Literature DB >> 26403437

Drafting the proteome landscape of myeloid-derived suppressor cells.

María Gato1, Idoia Blanco-Luquin1, Maribel Zudaire1, Xabier Martínez de Morentin2, Estela Perez-Valderrama2, Aintzane Zabaleta3, Grazyna Kochan1, David Escors1, Joaquín Fernandez-Irigoyen2, Enrique Santamaría2.   

Abstract

Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of cells that are defined by their myeloid origin, immature state, and ability to potently suppress T-cell responses. They regulate immune responses and the population significantly increases in the tumor microenvironment of patients with glioma and other malignant tumors. For their study, MDSCs are usually isolated from the spleen or directly of tumors from a large number of tumor-bearing mice although promising ex vivo differentiated MDSC production systems have been recently developed. During the last years, proteomics has emerged as a powerful approach to analyze MDSCs proteomes using shotgun-based mass spectrometry (MS), providing functional information about cellular homeostasis and metabolic state at a global level. Here, we will revise recent proteome profiling studies performed in MDSCs from different origins. Moreover, we will perform an integrative functional analysis of the protein compilation derived from these large-scale proteomic studies in order to obtain a comprehensive view of MDSCs biology. Finally, we will also discuss the potential application of high-throughput proteomic approaches to study global proteome dynamics and post-translational modifications (PTMs) during the differentiation process of MDSCs that will greatly boost the identification of novel MDSC-specific therapeutic targets to apply in cancer immunotherapy.
© 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  Biomedicine; Mass spectrometry; Myeloid-derived suppressor cell; Pathway; Proteomics

Mesh:

Substances:

Year:  2015        PMID: 26403437     DOI: 10.1002/pmic.201500229

Source DB:  PubMed          Journal:  Proteomics        ISSN: 1615-9853            Impact factor:   3.984


  12 in total

Review 1.  Myeloid-Derived Suppressor Cells: Immune-Suppressive Cells That Impair Antitumor Immunity and Are Sculpted by Their Environment.

Authors:  Suzanne Ostrand-Rosenberg; Catherine Fenselau
Journal:  J Immunol       Date:  2018-01-15       Impact factor: 5.422

Review 2.  Neutrophils and PMN-MDSC: Their biological role and interaction with stromal cells.

Authors:  Jie Zhou; Yulia Nefedova; Aihua Lei; Dmitry Gabrilovich
Journal:  Semin Immunol       Date:  2017-12-15       Impact factor: 11.130

3.  Selective targeting of different populations of myeloid-derived suppressor cells by histone deacetylase inhibitors.

Authors:  Ayumi Hashimoto; Takeshi Fukumoto; Rugang Zhang; Dmitry Gabrilovich
Journal:  Cancer Immunol Immunother       Date:  2020-05-20       Impact factor: 6.968

Review 4.  Myeloid-Derived Suppressor Cells.

Authors:  Dmitry I Gabrilovich
Journal:  Cancer Immunol Res       Date:  2017-01       Impact factor: 11.151

Review 5.  Targeting myeloid-derived suppressor cells to enhance natural killer cell-based immunotherapy.

Authors:  Shweta Joshi; Andrew Sharabi
Journal:  Pharmacol Ther       Date:  2022-02-02       Impact factor: 13.400

Review 6.  Plasticity of myeloid-derived suppressor cells in cancer.

Authors:  Evgenii Tcyganov; Jerome Mastio; Eric Chen; Dmitry I Gabrilovich
Journal:  Curr Opin Immunol       Date:  2018-03-14       Impact factor: 7.486

Review 7.  Myeloid-derived suppressor cells coming of age.

Authors:  Filippo Veglia; Michela Perego; Dmitry Gabrilovich
Journal:  Nat Immunol       Date:  2018-01-18       Impact factor: 25.606

Review 8.  Cancer-Associated Myeloid Regulatory Cells.

Authors:  Yannick De Vlaeminck; Anna González-Rascón; Cleo Goyvaerts; Karine Breckpot
Journal:  Front Immunol       Date:  2016-03-29       Impact factor: 7.561

Review 9.  Tumor-derived exosomes, myeloid-derived suppressor cells, and tumor microenvironment.

Authors:  Xinyu Tian; Han Shen; Zhiyang Li; Tingting Wang; Shengjun Wang
Journal:  J Hematol Oncol       Date:  2019-08-22       Impact factor: 17.388

Review 10.  Resistance to PD-L1/PD-1 Blockade Immunotherapy. A Tumor-Intrinsic or Tumor-Extrinsic Phenomenon?

Authors:  Luisa Chocarro de Erauso; Miren Zuazo; Hugo Arasanz; Ana Bocanegra; Carlos Hernandez; Gonzalo Fernandez; Maria Jesus Garcia-Granda; Ester Blanco; Ruth Vera; Grazyna Kochan; David Escors
Journal:  Front Pharmacol       Date:  2020-04-07       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.